These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 37120540)

  • 1. Functional genomics in stroke: current and future applications of iPSCs and gene editing to dissect the function of risk variants.
    Granata A
    BMC Cardiovasc Disord; 2023 Apr; 23(1):223. PubMed ID: 37120540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association.
    Musunuru K; Sheikh F; Gupta RM; Houser SR; Maher KO; Milan DJ; Terzic A; Wu JC;
    Circ Genom Precis Med; 2018 Jan; 11(1):e000043. PubMed ID: 29874173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-Generated and Gene-Edited Induced Pluripotent Stem Cells for Disease Modeling and Therapy.
    Kehler J; Greco M; Martino V; Pachiappan M; Yokoe H; Chen A; Yang M; Auerbach J; Jessee J; Gotte M; Milanesi L; Albertini A; Bellipanni G; Zucchi I; Reinbold RA; Giordano A
    J Cell Physiol; 2017 Jun; 232(6):1262-1269. PubMed ID: 27631155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome editing in pluripotent stem cells: research and therapeutic applications.
    Deleidi M; Yu C
    Biochem Biophys Res Commun; 2016 May; 473(3):665-74. PubMed ID: 26930470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene correction in patient-specific iPSCs for therapy development and disease modeling.
    Jang YY; Ye Z
    Hum Genet; 2016 Sep; 135(9):1041-58. PubMed ID: 27256364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Induced pluripotent stem cell technology and its application in disease research].
    Cai CY; Meng FL; Rao L; Liu YY; Zhao XL
    Yi Chuan; 2020 Nov; 42(11):1042-1061. PubMed ID: 33229312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of induced pluripotent stem cell technology for the investigation of hematological disorders.
    Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A
    Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Updates on Induced Pluripotent Stem Cells in Hematological Disorders.
    Wattanapanitch M
    Stem Cells Int; 2019; 2019():5171032. PubMed ID: 31191673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
    Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
    Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling.
    Zhu D; Kong CSL; Gingold JA; Zhao R; Lee DF
    Adv Exp Med Biol; 2018; 1119():169-183. PubMed ID: 30069853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining Induced Pluripotent Stem Cells and Genome Editing Technologies for Clinical Applications.
    Chang CY; Ting HC; Su HL; Jeng JR
    Cell Transplant; 2018 Mar; 27(3):379-392. PubMed ID: 29806481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
    Dannenmann B; Nasri M; Welte K; Skokowa J
    Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell contributions to neurological disease modeling and personalized medicine.
    Liang N; Trujillo CA; Negraes PD; Muotri AR; Lameu C; Ulrich H
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt A):54-62. PubMed ID: 28576415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of induced pluripotent stem cells in lysosomal storage diseases.
    Kido J; Nakamura K; Era T
    Mol Cell Neurosci; 2020 Oct; 108():103540. PubMed ID: 32828964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications.
    Omole AE; Fakoya AOJ
    PeerJ; 2018; 6():e4370. PubMed ID: 29770269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced pluripotent stem cell technology: a decade of progress.
    Shi Y; Inoue H; Wu JC; Yamanaka S
    Nat Rev Drug Discov; 2017 Feb; 16(2):115-130. PubMed ID: 27980341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Path from schizophrenia genomics to biology: gene regulation and perturbation in neurons derived from induced pluripotent stem cells and genome editing.
    Duan J
    Neurosci Bull; 2015 Feb; 31(1):113-27. PubMed ID: 25575480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted mutagenesis in human iPSCs using CRISPR genome-editing tools.
    Long Y; Cech TR
    Methods; 2021 Jul; 191():44-58. PubMed ID: 33444739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR Base Editing in Induced Pluripotent Stem Cells.
    Chang YJ; Xu CL; Cui X; Bassuk AG; Mahajan VB; Tsai YT; Tsang SH
    Methods Mol Biol; 2019; 2045():337-346. PubMed ID: 31250381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.